In	O
vivo	O
anergized	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
express	O
perturbed	O
AP-1	O
and	O
NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
.	O

Anergy	O
is	O
a	O
major	O
mechanism	O
to	O
ensure	O
antigen-specific	O
tolerance	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
in	O
the	O
adult	O
.	O

In	O
vivo	O
,	O
anergy	O
has	O
mainly	O
been	O
studied	O
at	O
the	O
cellular	O
level	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
the	O
T-cell-activating	B-protein
superantigen	I-protein
staphylococcal	B-protein
enterotoxin	I-protein
A	I-protein
(	O
SEA	B-protein
)	O
to	O
investigate	O
molecular	O
mechanisms	O
of	O
T-lymphocyte	O
anergy	O
in	O
vivo	O
.	O

Injection	O
of	O
SEA	B-protein
to	O
adult	O
mice	O
activates	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
expressing	O
certain	O
T-cell	B-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
variable	I-protein
region	I-protein
beta-chain	I-protein
families	I-protein
and	O
induces	O
strong	O
and	O
rapid	O
production	O
of	O
interleukin	O
2	O
(	O
IL-2	B-protein
)	O
.	O

In	O
contrast	O
,	O
repeated	O
injections	O
of	O
SEA	B-protein
cause	O
CD4+	B-cell_type
T-cell	I-cell_type
deletion	O
and	O
anergy	O
in	O
the	O
remaining	O
CD4+	O
T	B-cell_type
cells	I-cell_type
,	O
characterized	O
by	O
reduced	O
expression	O
of	O
IL-2	B-protein
at	O
mRNA	O
and	O
protein	O
levels	O
.	O

We	O
analyzed	O
expression	O
of	O
AP-1	B-protein
,	O
NF-kappa	B-protein
B	I-protein
,	O
NF-AT	B-protein
,	O
and	O
octamer	B-protein
binding	I-protein
transcription	I-protein
factors	I-protein
,	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
IL-2	B-protein
gene	O
promoter	O
activity	O
.	O

Large	O
amounts	O
of	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
and	O
significant	O
quantities	O
of	O
NF-AT	B-protein
were	O
induced	O
in	O
SEA-activated	B-cell_line
CD4+	I-cell_line
spleen	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
whereas	O
Oct-1	O
and	O
Oct-2	O
DNA	O
binding	O
activity	O
was	O
similar	O
in	O
both	O
resting	O
and	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
anergic	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
contained	O
severely	O
reduced	O
levels	O
of	O
AP-1	B-protein
and	O
Fos/Jun-containing	B-protein
NF-AT	I-protein
complexes	I-protein
but	O
expressed	O
significant	O
amounts	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
Oct	B-protein
binding	I-protein
proteins	I-protein
after	O
SEA	B-protein
stimulation	O
.	O

Resolution	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
demonstrated	O
predominant	O
expression	O
of	O
p50-p65	B-protein
heterodimers	I-protein
in	O
activated	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
while	O
anergic	O
cells	O
mainly	O
expressed	O
the	O
transcriptionally	O
inactive	O
p50	B-protein
homodimer	I-protein
.	O

These	O
alterations	O
of	O
transcription	B-protein
factors	I-protein
are	O
likely	O
to	O
be	O
responsible	O
for	O
repression	O
of	O
IL-2	B-protein
in	O
anergic	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

93	NULL
,	NULL
Pp	NULL
.	NULL

979-984	NULL
,	NULL
February	NULL
1996	NULL
Immunology	NULL
In	NULL
vivo	NULL
anergized	NULL
CD4*	NULL
T	NULL
cells	NULL
express	NULL
perturbed	NULL
AP-1	NULL
and	NULL
NF-B	NULL
transcription	NULL
factors	NULL
(	NULL
superantigen/T	NULL
lymphocyte/interleukin	NULL
2	NULL
gene	NULL
regulation/transcription	NULL
factor	NULL
)	NULL
ANETTE	NULL
SUNDSTEDT*	NULL
,	NULL
MIKAEL	NULL
SigGvarRDssoN*t	NULL
,	NULL
ToMAS	NULL
LEANDERsONT	NULL
,	NULL
GunnaR	NULL
TERJE	NULL
KALLAND*	NULL
#	NULL
,	NULL
AND	NULL
MIKAEL	NULL
DonLstTEN*	NULL
#	NULL
§	NULL
*Pharmacia	NULL
Oncology	NULL
Immunology	NULL
,	NULL
Scheeleviigen	NULL
22	NULL
,	NULL
S-223	NULL
63	NULL
Lund	NULL
,	NULL
Sweden	NULL
;	NULL
Departments	NULL
of	NULL
*I'mmunology	NULL
and	NULL
Tumor	NULL
Immunology	NULL
,	NULL
The	NULL
Wallenberg	NULL
Laboratory	NULL
,	NULL
University	NULL
of	NULL
Lund	NULL
,	NULL
Lund	NULL
,	NULL
Sweden	NULL
Communicated	NULL
by	NULL
John	NULL
W.	NULL
Kappler	NULL
,	NULL
National	NULL
Jewish	NULL
Center	NULL
for	NULL
Immunology	NULL
and	NULL
Respiratory	NULL
Medicine	NULL
,	NULL
Denver	NULL
,	NULL
CO	NULL
,	NULL
September	NULL
29	NULL
,	NULL
1995	NULL
ABSTRACT	NULL
Anergy	NULL
is	NULL
a	NULL
major	NULL
mechanism	NULL
to	NULL
ensure	NULL
antigen-specific	NULL
tolerance	NULL
in	NULL
T	NULL
lymphocytes	NULL
in	NULL
the	NULL
adult	NULL
.	NULL

In	NULL
vivo	NULL
,	NULL
anergy	NULL
has	NULL
mainly	NULL
been	NULL
studied	NULL
at	NULL
the	NULL
cellular	NULL
level	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
used	NULL
the	NULL
T-cell-activating	NULL
superantigen	NULL
staphylococcal	NULL
enterotoxin	NULL
A	NULL
(	NULL
SEA	NULL
)	NULL
to	NULL
investigate	NULL
molecular	NULL
mechanisms	NULL
of	NULL
T-lymphocyte	NULL
anergy	NULL
in	NULL
vivo	NULL
.	NULL

Injection	NULL
of	NULL
SEA	NULL
to	NULL
adult	NULL
mice	NULL
activates	NULL
CD4*	NULL
T	NULL
cells	NULL
expressing	NULL
certain	NULL
T-cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
variable	NULL
region	NULL
B-chain	NULL
families	NULL
and	NULL
induces	NULL
strong	NULL
and	NULL
rapid	NULL
production	NULL
of	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
repeated	NULL
injections	NULL
of	NULL
SEA	NULL
cause	NULL
CD4+*	NULL
T-cell	NULL
deletion	NULL
and	NULL
anergy	NULL
in	NULL
the	NULL
remaining	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
characterized	NULL
by	NULL
reduced	NULL
expression	NULL
of	NULL
IL-2	NULL
at	NULL
mRNA	NULL
and	NULL
protein	NULL
levels	NULL
.	NULL

We	NULL
analyzed	NULL
expression	NULL
of	NULL
AP-1	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
NF-AT	NULL
,	NULL
and	NULL
octamer	NULL
binding	NULL
transcription	NULL
factors	NULL
,	NULL
which	NULL
are	NULL
known	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
IL-2	NULL
gene	NULL
promoter	NULL
activity	NULL
.	NULL

Large	NULL
amounts	NULL
of	NULL
AP-1	NULL
and	NULL
NF-xB	NULL
and	NULL
significant	NULL
quantities	NULL
of	NULL
NF-AT	NULL
were	NULL
induced	NULL
in	NULL
SEA-activated	NULL
CD4+*	NULL
spleen	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
similar	NULL
in	NULL
both	NULL
resting	NULL
and	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
anergic	NULL
CD4+*	NULL
T	NULL
cells	NULL
contained	NULL
severely	NULL
reduced	NULL
levels	NULL
of	NULL
AP-1	NULL
and	NULL
Fos	NULL
/Jun-containing	NULL
NF-AT	NULL
complexes	NULL
but	NULL
expressed	NULL
significant	NULL
amounts	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Oct	NULL
binding	NULL
proteins	NULL
after	NULL
SEA	NULL
stimulation	NULL
.	NULL

Resolution	NULL
of	NULL
the	NULL
complex	NULL
demonstrated	NULL
predominant	NULL
expression	NULL
of	NULL
p50-p65	NULL
heterodimers	NULL
in	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
while	NULL
anergic	NULL
cells	NULL
mainly	NULL
expressed	NULL
the	NULL
transcriptionally	NULL
inactive	NULL
p50	NULL
homodimer	NULL
.	NULL

These	NULL
alterations	NULL
of	NULL
transcription	NULL
factors	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
responsible	NULL
for	NULL
repression	NULL
of	NULL
IL-2	NULL
in	NULL
anergic	NULL
T	NULL
cells	NULL
.	NULL

Staphylococcal	NULL
enterotoxins	NULL
(	NULL
SEs	NULL
)	NULL
belong	NULL
to	NULL
a	NULL
family	NULL
of	NULL
bacterial	NULL
proteins	NULL
denoted	NULL
as	NULL
superantigens	NULL
(	NULL
SAgs	NULL
)	NULL
because	NULL
of	NULL
their	NULL
ability	NULL
to	NULL
activate	NULL
a	NULL
high	NULL
frequency	NULL
of	NULL
both	NULL
CD4*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
expressing	NULL
certain	NULL
T-cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
variable	NULL
region	NULL
B	NULL
chains	NULL
(	NULL
V	NULL
;	NULL
)	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Administration	NULL
of	NULL
SE	NULL
to	NULL
adult	NULL
mice	NULL
induces	NULL
rapid	NULL
production	NULL
of	NULL
a	NULL
panel	NULL
of	NULL
cytokines	NULL
,	NULL
including	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
,	NULL
and	NULL
subsequent	NULL
expansion	NULL
of	NULL
reactive	NULL
T-cell	NULL
populations	NULL
(	NULL
3	NULL
)	NULL
.	NULL

After	NULL
the	NULL
initial	NULL
phase	NULL
of	NULL
SE-induced	NULL
activation	NULL
in	NULL
vivo	NULL
,	NULL
part	NULL
of	NULL
the	NULL
reactive	NULL
CD4*	NULL
T	NULL
cells	NULL
are	NULL
deleted	NULL
and	NULL
the	NULL
remaining	NULL
CD4*	NULL
T-cell	NULL
population	NULL
fails	NULL
to	NULL
proliferate	NULL
and	NULL
secrete	NULL
IL-2	NULL
in	NULL
response	NULL
to	NULL
a	NULL
subsequent	NULL
SE	NULL
challenge	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Production	NULL
of	NULL
IL-2	NULL
in	NULL
CD4*	NULL
T	NULL
cells	NULL
is	NULL
strongly	NULL
regulated	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
(	NULL
5	NULL
)	NULL
.	NULL

The	NULL
IL-2	NULL
promoter/enhancer	NULL
(	NULL
6	NULL
)	NULL
consists	NULL
of	NULL
several	NULL
DNA	NULL
response	NULL
elements	NULL
,	NULL
including	NULL
proximal	NULL
and	NULL
distal	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
binding	NULL
sites	NULL
,	NULL
NF-IL2A	NULL
and	NULL
NF-IL2D	NULL
that	NULL
bind	NULL
octamer	NULL
proteins	NULL
,	NULL
a	NULL
single	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
site	NULL
,	NULL
and	NULL
a	NULL
NF-	NULL
«	NULL
B-like	NULL
CD28	NULL
response	NULL
element	NULL
(	NULL
CD28RE	NULL
)	NULL
,	NULL
which	NULL
are	NULL
all	NULL
recognized	NULL
by	NULL
specific	NULL
transacting	NULL
proteins	NULL
.	NULL

Each	NULL
one	NULL
of	NULL
these	NULL
transcription	NULL
factors	NULL
is	NULL
regulated	NULL
specifically	NULL
(	NULL
7	NULL
)	NULL
and	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
contribute	NULL
significantly	NULL
to	NULL
the	NULL
activity	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

979	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
8	NULL
)	NULL
.	NULL

The	NULL
AP-1	NULL
family	NULL
of	NULL
proteins	NULL
includes	NULL
a	NULL
number	NULL
of	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
(	NULL
9-11	NULL
)	NULL
.	NULL

The	NULL
Rel	NULL
family	NULL
of	NULL
proteins	NULL
includes	NULL
p50	NULL
,	NULL
p65	NULL
,	NULL
and	NULL
c-Rel	NULL
proteins	NULL
,	NULL
which	NULL
may	NULL
bind	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
element	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
protein	NULL
complexes	NULL
,	NULL
such	NULL
as	NULL
the	NULL
highly	NULL
transcriptionally	NULL
active	NULL
p50-p65	NULL
heterodimer	NULL
or	NULL
the	NULL
less	NULL
active	NULL
p50-p50	NULL
homodimer	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

The	NULL
Fos/Jun	NULL
and	NULL
Rel	NULL
families	NULL
of	NULL
proteins	NULL
seem	NULL
to	NULL
be	NULL
of	NULL
major	NULL
importance	NULL
in	NULL
regulating	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
since	NULL
they	NULL
may	NULL
themselves	NULL
bind	NULL
to	NULL
their	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
elements	NULL
and	NULL
further	NULL
participate	NULL
with	NULL
other	NULL
proteins	NULL
to	NULL
form	NULL
an	NULL
active	NULL
NF-AT	NULL
and	NULL
CD28RE	NULL
binding	NULL
complex	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

Anergy	NULL
was	NULL
originally	NULL
described	NULL
by	NULL
Schwartz	NULL
and	NULL
co-workers	NULL
using	NULL
an	NULL
in	NULL
vitro	NULL
model	NULL
with	NULL
T-cell	NULL
clones	NULL
,	NULL
which	NULL
were	NULL
rendered	NULL
anergic	NULL
by	NULL
antigen	NULL
presentation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
appropriate	NULL
costimulatory	NULL
signals	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Studies	NULL
of	NULL
these	NULL
antigen-specific	NULL
T-cell	NULL
clones	NULL
have	NULL
shown	NULL
that	NULL
lack	NULL
of	NULL
IL-2	NULL
production	NULL
,	NULL
a	NULL
hallmark	NULL
of	NULL
anergy	NULL
,	NULL
correlates	NULL
with	NULL
reduced	NULL
levels	NULL
of	NULL
the	NULL
AP-1	NULL
transcription	NULL
factor	NULL
(	NULL
17	NULL
)	NULL
.	NULL

We	NULL
now	NULL
demonstrate	NULL
that	NULL
in	NULL
vivo	NULL
anergized	NULL
T	NULL
cells	NULL
express	NULL
diminished	NULL
amounts	NULL
of	NULL
AP-1	NULL
and	NULL
NF-AT/AP-1	NULL
(	NULL
18	NULL
)	NULL
binding	NULL
complexes	NULL
compared	NULL
to	NULL
SAg-activated	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
anergic	NULL
cells	NULL
were	NULL
further	NULL
shown	NULL
to	NULL
retain	NULL
the	NULL
ability	NULL
to	NULL
mobilize	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

However	NULL
,	NULL
while	NULL
the	NULL
induced	NULL
NF-	NULL
«	NULL
B	NULL
complex	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
was	NULL
mainly	NULL
composed	NULL
of	NULL
the	NULL
p50-p65	NULL
heterodimer	NULL
,	NULL
anergic	NULL
T	NULL
cells	NULL
predominantly	NULL
contained	NULL
the	NULL
p50	NULL
homodimer	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
in	NULL
vivo	NULL
anergized	NULL
CD4*	NULL
T	NULL
cells	NULL
may	NULL
have	NULL
a	NULL
more	NULL
complex	NULL
perturbation	NULL
in	NULL
IL-2	NULL
gene	NULL
promoter-related	NULL
transcription	NULL
factors	NULL
than	NULL
was	NULL
inferred	NULL
from	NULL
the	NULL
in	NULL
vitro	NULL
anergy	NULL
model	NULL
(	NULL
17	NULL
)	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Animals	NULL
and	NULL
Treatment	NULL
.	NULL

Transgenic	NULL
(	NULL
TG	NULL
)	NULL
C57BL/6	NULL
mice	NULL
expressing	NULL
a	NULL
rearranged	NULL
TCR	NULL
V	NULL
;	NULL
3	NULL
gene	NULL
under	NULL
the	NULL
influence	NULL
of	NULL
an	NULL
inserted	NULL
immunoglobulin	NULL
heavy-chain	NULL
enhancer	NULL
(	NULL
19	NULL
)	NULL
were	NULL
generously	NULL
provided	NULL
by	NULL
M.	NULL
Davis	NULL
(	NULL
Stanford	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
TG	NULL
TCR	NULL
V	NULL
;	NULL
3	NULL
mice	NULL
expressed	NULL
85-95	NULL
%	NULL
of	NULL
TCR	NULL
V	NULL
»	NULL
3	NULL
in	NULL
the	NULL
CD3+	NULL
T-cell	NULL
population	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Recombinant	NULL
SEA	NULL
was	NULL
expressed	NULL
in	NULL
Escherichia	NULL
coli	NULL
and	NULL
purified	NULL
to	NULL
homogeneity	NULL
as	NULL
described	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Various	NULL
doses	NULL
of	NULL
SEA	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
with	NULL
1	NULL
%	NULL
normal	NULL
syngeneic	NULL
serum	NULL
(	NULL
PBS	NULL
)	NULL
or	NULL
in	NULL
PBS	NULL
alone	NULL
were	NULL
injected	NULL
i.v	NULL
.	NULL

at	NULL
4-day	NULL
intervals	NULL
.	NULL

Reagents	NULL
.	NULL

Monoclonal	NULL
antibodies	NULL
(	NULL
mAbs	NULL
)	NULL
directed	NULL
to	NULL
murine	NULL
CD3	NULL
,	NULL
CD4	NULL
,	NULL
CD8	NULL
,	NULL
and	NULL
TCR	NULL
Vp	NULL
;	NULL
3	NULL
were	NULL
purchased	NULL
from	NULL
PharMingen	NULL
.	NULL

Recombinant	NULL
murine	NULL
IL-2	NULL
and	NULL
mAbs	NULL
to	NULL
murine	NULL
IL-2	NULL
(	NULL
JES6-1A12	NULL
and	NULL
JES6-5H4	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
PharMingen	NULL
.	NULL

Polyclonal	NULL
antisera	NULL
directed	NULL
to	NULL
members	NULL
of	NULL
the	NULL
AP-1	NULL
complex	NULL
[	NULL
c-Fos	NULL
(	NULL
se-52	NULL
)	NULL
,	NULL
Fra-1	NULL
(	NULL
se-183	NULL
)	NULL
,	NULL
Fra-2	NULL
(	NULL
se-171	NULL
)	NULL
,	NULL
c-Jun	NULL
(	NULL
se-45	NULL
)	NULL
,	NULL
JunB	NULL
(	NULL
sc-46	NULL
)	NULL
,	NULL
JunD	NULL
(	NULL
se-75	NULL
)	NULL
,	NULL
pan-Fos	NULL
members	NULL
(	NULL
se-253	NULL
)	NULL
]	NULL
and	NULL
Abbreviations	NULL
:	NULL
SAg	NULL
,	NULL
superantigen	NULL
;	NULL
SEA	NULL
,	NULL
staphylococcal	NULL
enterotoxin	NULL
A	NULL
;	NULL
IL-2	NULL
,	NULL
interleukin	NULL
2	NULL
;	NULL
TNF	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
;	NULL
TG	NULL
,	NULL
transgenic	NULL
;	NULL
TCR	NULL
,	NULL
T-cell	NULL
receptor	NULL
;	NULL
Vs	NULL
,	NULL
variable	NULL
region	NULL
8	NULL
chain	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
;	NULL
RT	NULL
,	NULL
reverse	NULL
transcription	NULL
.	NULL

$	NULL
To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

980	NULL
Immunology	NULL
:	NULL
Sundstedt	NULL
et	NULL
al	NULL
.	NULL

the	NULL
NF-	NULL
«	NULL
B	NULL
gene	NULL
family	NULL
[	NULL
¢c-Rei	NULL
(	NULL
sc-70	NULL
)	NULL
,	NULL
p50	NULL
(	NULL
se-1	NULL
14	NULL
)	NULL
,	NULL
p65	NULL
(	NULL
sc-109	NULL
)	NULL
]	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
for	NULL
antibody	NULL
supershift	NULL
analysis	NULL
.	NULL

A	NULL
polyclonal	NULL
rabbit	NULL
antiserum	NULL
against	NULL
recombinant	NULL
NF-AT	NULL
,	NULL
(	NULL
20	NULL
)	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
A.	NULL
Rao	NULL
(	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Boston	NULL
)	NULL
.	NULL

A	NULL
control	NULL
extract	NULL
for	NULL
supershift	NULL
experiments	NULL
made	NULL
from	NULL
phorbol	NULL
ester-stimulated	NULL
mouse	NULL
fibroblasts	NULL
(	NULL
sc-2125	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
.	NULL

IL-2	NULL
Serum	NULL
Levels	NULL
.	NULL

Blood	NULL
samples	NULL
were	NULL
drawn	NULL
at	NULL
various	NULL
time	NULL
points	NULL
after	NULL
i.v	NULL
.	NULL

injections	NULL
of	NULL
SEA	NULL
or	NULL
PBS	NULL
and	NULL
tested	NULL
for	NULL
IL-2	NULL
content	NULL
by	NULL
a	NULL
specific	NULL
ELISA	NULL
using	NULL
mAbs	NULL
JES6-1A12	NULL
and	NULL
JES6-5H4	NULL
according	NULL
to	NULL
instructions	NULL
from	NULL
the	NULL
manufacturer	NULL
.	NULL

All	NULL
groups	NULL
contained	NULL
pooled	NULL
sera	NULL
from	NULL
at	NULL
least	NULL
two	NULL
mice	NULL
.	NULL

Reverse	NULL
Transcription	NULL
(	NULL
RT	NULL
)	NULL
-PCR	NULL
.	NULL

Spleens	NULL
were	NULL
prepared	NULL
from	NULL
mice	NULL
injected	NULL
i.v	NULL
.	NULL

with	NULL
SEA	NULL
or	NULL
PBS	NULL
at	NULL
different	NULL
times	NULL
before	NULL
analyses	NULL
of	NULL
IL-2	NULL
and	NULL
B-actin	NULL
mRNA	NULL
levels	NULL
by	NULL
a	NULL
semi-quantitative	NULL
RT-PCR	NULL
assay	NULL
as	NULL
described	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
relative	NULL
amount	NULL
of	NULL
IL-2	NULL
mRNA	NULL
was	NULL
calculated	NULL
by	NULL
the	NULL
formula	NULL
(	NULL
cpm	NULL
test	NULL
-	NULL
cpm	NULL
no	NULL
cDNA	NULL
control	NULL
)	NULL
/	NULL
(	NULL
{	NULL
epm	NULL
B-actin	NULL
test	NULL
-	NULL
cpm	NULL
no	NULL
cDNA	NULL
control	NULL
)	NULL
.	NULL

Cell	NULL
Separation	NULL
.	NULL

Spleens	NULL
were	NULL
prepared	NULL
from	NULL
mice	NULL
injected	NULL
i.v	NULL
.	NULL

with	NULL
SEA	NULL
or	NULL
PBS	NULL
at	NULL
different	NULL
times	NULL
before	NULL
analysis	NULL
.	NULL

Purified	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
>	NULL
95	NULL
%	NULL
CD4*	NULL
as	NULL
determined	NULL
by	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
analysis	NULL
)	NULL
were	NULL
obtained	NULL
by	NULL
positive	NULL
selection	NULL
using	NULL
magnetic	NULL
beads	NULL
coated	NULL
with	NULL
anti-CD4	NULL
mAb	NULL
(	NULL
Milt-enyi	NULL
Biotec	NULL
GmbH	NULL
,	NULL
Bergisch	NULL
Gladbach	NULL
,	NULL
Germany	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Preparation	NULL
of	NULL
Nuclear	NULL
Extracts	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
made	NULL
according	NULL
to	NULL
the	NULL
method	NULL
described	NULL
by	NULL
Schreiber	NULL
et	NULL
al	NULL
.	NULL

(	NULL
21	NULL
)	NULL
;	NULL
5-10	NULL
x	NULL
10°	NULL
purified	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
were	NULL
used	NULL
for	NULL
extraction	NULL
and	NULL
the	NULL
nuclear	NULL
proteins	NULL
were	NULL
finally	NULL
dissolved	NULL
in	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9/0.4	NULL
M	NULL
NaCl/1	NULL
mM	NULL
EDTA/1	NULL
mM	NULL
EGTA/1	NULL
mM	NULL
dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
/1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride/	NULL
0.5	NULL
ug	NULL
of	NULL
leupeptin	NULL
per	NULL
mi/0.7	NULL
ug	NULL
of	NULL
pepstatin	NULL
per	NULL
ml/1	NULL
ug	NULL
of	NULL
trypsin	NULL
inhibitor	NULL
type	NULL
S	NULL
per	NULL
ml	NULL
.	NULL

For	NULL
NF-AT	NULL
binding	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
1-2	NULL
x	NULL
10°	NULL
spleen	NULL
cells	NULL
using	NULL
the	NULL
method	NULL
described	NULL
by	NULL
Choi	NULL
et	NULL
al	NULL
.	NULL

(	NULL
22	NULL
)	NULL
.	NULL

Protein	NULL
concentration	NULL
of	NULL
all	NULL
extracts	NULL
was	NULL
measured	NULL
with	NULL
the	NULL
Bio-Rad	NULL
protein	NULL
assay	NULL
kit	NULL
(	NULL
Bio-Rad	NULL
)	NULL
,	NULL
and	NULL
the	NULL
extracts	NULL
were	NULL
stored	NULL
in	NULL
aliquots	NULL
of	NULL
-70°C	NULL
until	NULL
required	NULL
.	NULL

Gel	NULL
Mobility-Shift	NULL
Assay	NULL
(	NULL
Gel	NULL
Shift	NULL
)	NULL
.	NULL

The	NULL
oligonucleotides	NULL
used	NULL
contained	NULL
the	NULL
following	NULL
sequences	NULL
:	NULL
Oct	NULL
binding	NULL
site	NULL
,	NULL
AP-1	NULL
consensus	NULL
,	NULL
5	NULL
!	NULL

-CTAGTGATGAGTCAGCCGGATC-3	NULL
'	NULL
;	NULL
NF-	NULL
«	NULL
B	NULL
consensus	NULL
,	NULL
5-GATCGAGGGGACTTTCCCTAGC-3	NULL
'	NULL
;	NULL
distal	NULL
NF-AT	NULL
site	NULL
of	NULL
murine	NULL
IL-2	NULL
promoter	NULL
,	NULL
5-GATCG-CCCAAAGAGGAAAATTTGTTTCATACAG-3	NULL
'	NULL
;	NULL
NF-AT	NULL
nonbinding	NULL
M3	NULL
mutant	NULL
,	NULL
5-GATCGCCCAAAGACCTTA-ATTTGTTTCATACAG-3	NULL
'	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
probes	NULL
were	NULL
end-labeled	NULL
with	NULL
[	NULL
y-	NULL
>	NULL
P	NULL
]	NULL
JATP	NULL
using	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
(	NULL
Pro-mega	NULL
)	NULL
according	NULL
to	NULL
instructions	NULL
from	NULL
the	NULL
manufacturer	NULL
and	NULL
purified	NULL
on	NULL
5	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
in	NULL
1	NULL
%	NULL
TBE	NULL
(	NULL
89	NULL
mM	NULL
Tris/89	NULL
mM	NULL
boric	NULL
acid/2	NULL
mM	NULL
EDTA	NULL
)	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
protein	NULL
in	NULL
each	NULL
mixture	NULL
(	NULL
0.5-1	NULL
ug	NULL
)	NULL
in	NULL
10	NULL
mM	NULL
TrissHCl	NULL
,	NULL
pH	NULL
7.5/50	NULL
mM	NULL
NaCl/1	NULL
mM	NULL
EDTA/1	NULL
mM	NULL
DTT/5	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
glycerol/2	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Pharmacia	NULL
)	NULL
for	NULL
AP-1	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
and	NULL
Oct	NULL
binding	NULL
.	NULL

To	NULL
detect	NULL
NF-AT	NULL
binding	NULL
,	NULL
5	NULL
ug	NULL
of	NULL
protein	NULL
was	NULL
used	NULL
in	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9/40	NULL
mM	NULL
KCI/2.5	NULL
mM	NULL
MgCl	NULL
;	NULL
/1	NULL
mM	NULL
DTT/4	NULL
%	NULL
Ficoll/2	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
.	NULL

The	NULL
reaction	NULL
mixtures	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
30	NULL
min	NULL
with	NULL
15,000	NULL
cpm	NULL
of	NULL
double-stranded	NULL
*P-labeled	NULL
oligonucleotides	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
electrophoresed	NULL
on	NULL
5	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
in	NULL
1	NULL
%	NULL
TBE	NULL
.	NULL

Unlabeled	NULL
oligonucleotides	NULL
,	NULL
used	NULL
for	NULL
competition	NULL
,	NULL
were	NULL
added	NULL
to	NULL
nuclear	NULL
extracts	NULL
and	NULL
dI-dC	NULL
before	NULL
addition	NULL
of	NULL
the	NULL
labeled	NULL
probe	NULL
.	NULL

For	NULL
supershift	NULL
analyses	NULL
,	NULL
the	NULL
mixture	NULL
of	NULL
nuclear	NULL
extract	NULL
and	NULL
labeled	NULL
oligonucleotide	NULL
was	NULL
incubated	NULL
with	NULL
1-2	NULL
pg	NULL
of	NULL
Abs	NULL
against	NULL
various	NULL
transcription	NULL
factors	NULL
for	NULL
1	NULL
hr	NULL
on	NULL
ice	NULL
.	NULL

No	NULL
effect	NULL
was	NULL
observed	NULL
with	NULL
control	NULL
IgG	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Control	NULL
experiments	NULL
performed	NULL
with	NULL
a	NULL
mixture	NULL
of	NULL
Abs	NULL
and	NULL
DNA	NULL
probe	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
protein	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
extract	NULL
demonstrated	NULL
that	NULL
none	NULL
of	NULL
the	NULL
Abs	NULL
used	NULL
bound	NULL
directly	NULL
to	NULL
the	NULL
DNA	NULL
target	NULL
sequences	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

For	NULL
NF-AT	NULL
supershift	NULL
analysis	NULL
,	NULL
Abs	NULL
were	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
before	NULL
addition	NULL
of	NULL
labeled	NULL
oligonucleotide	NULL
.	NULL

RESULTS	NULL
SEA-Induced	NULL
Anergy	NULL
Corresponds	NULL
to	NULL
Reduced	NULL
IL-2	NULL
Production	NULL
in	NULL
Vivo	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
used	NULL
TG	NULL
TCR	NULL
mice	NULL
as	NULL
a	NULL
sensitive	NULL
model	NULL
(	NULL
3	NULL
)	NULL
to	NULL
investigate	NULL
production	NULL
and	NULL
transcriptional	NULL
regulation	NULL
of	NULL
IL-2	NULL
in	NULL
SEA-activated	NULL
and	NULL
anergic	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
4	NULL
)	NULL
.	NULL

High	NULL
serum	NULL
levels	NULL
of	NULL
IL-2	NULL
protein	NULL
were	NULL
recorded	NULL
1-4	NULL
hr	NULL
after	NULL
SEA	NULL
priming	NULL
of	NULL
TG	NULL
TCR	NULL
V	NULL
;	NULL
3	NULL
mice	NULL
and	NULL
peak	NULL
response	NULL
was	NULL
seen	NULL
after	NULL
2	NULL
hr	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

However	NULL
,	NULL
when	NULL
the	NULL
mice	NULL
were	NULL
pretreated	NULL
with	NULL
two	NULL
injections	NULL
of	NULL
SEA	NULL
,	NULL
the	NULL
response	NULL
to	NULL
a	NULL
subsequent	NULL
SEA	NULL
challenge	NULL
was	NULL
strongly	NULL
reduced	NULL
at	NULL
all	NULL
tested	NULL
time	NULL
points	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

RT-PCR	NULL
analysis	NULL
revealed	NULL
that	NULL
IL-2	NULL
mRNA	NULL
was	NULL
also	NULL
decreased	NULL
after	NULL
three	NULL
SEA	NULL
injections	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Different	NULL
Patterns	NULL
of	NULL
Transcription	NULL
Factors	NULL
in	NULL
Activated	NULL
and	NULL
Anergic	NULL
T	NULL
Cells	NULL
.	NULL

To	NULL
evaluate	NULL
whether	NULL
the	NULL
parallel	NULL
decline	NULL
of	NULL
IL-2	NULL
mRNA	NULL
and	NULL
protein	NULL
levels	NULL
reflected	NULL
a	NULL
changed	NULL
expression	NULL
of	NULL
transcription	NULL
factors	NULL
binding	NULL
to	NULL
regulatory	NULL
elements	NULL
in	NULL
the	NULL
IL-2	NULL
gene	NULL
promoter	NULL
,	NULL
we	NULL
used	NULL
gel-shift	NULL
analysis	NULL
and	NULL
oligo-	NULL
-	NULL
#	NULL
-	NULL
1xSEA	NULL
-A-	NULL
3xSEA	NULL
800	NULL
0	NULL
2	NULL
4	NULL
6	NULL
8	NULL
time	NULL
after	NULL
inj	NULL
.	NULL

(	NULL
hrs	NULL
)	NULL
IL-2	NULL
mRNA	NULL
level	NULL
0	NULL
2	NULL
4	NULL
6	NULL
8	NULL
time	NULL
after	NULL
inj	NULL
.	NULL

(	NULL
hrs	NULL
)	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
FiG	NULL
.	NULL

1	NULL
.	NULL

Kinetics	NULL
of	NULL
IL-2	NULL
protein	NULL
and	NULL
mRNA	NULL
levels	NULL
after	NULL
SEA	NULL
treatment	NULL
.	NULL

Mice	NULL
were	NULL
treated	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
SEA	NULL
one	NULL
or	NULL
three	NULL
times	NULL
,	NULL
and	NULL
spleens	NULL
and	NULL
sera	NULL
were	NULL
taken	NULL
at	NULL
the	NULL
indicated	NULL
time	NULL
points	NULL
after	NULL
the	NULL
last	NULL
injection	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Protein	NULL
levels	NULL
were	NULL
analyzed	NULL
by	NULL
specific	NULL
ELISA	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Quantification	NULL
of	NULL
cytokine	NULL
mRNA	NULL
levels	NULL
was	NULL
performed	NULL
by	NULL
incorporation	NULL
of	NULL
[	NULL
a-2P	NULL
]	NULL
dCTP	NULL
and	NULL
expressed	NULL
relative	NULL
to	NULL
B-actin	NULL
.	NULL

(	NULL
C	NULL
)	NULL
PCR	NULL
products	NULL
at	NULL
two	NULL
dilutions	NULL
are	NULL
shown	NULL
.	NULL

Lanes	NULL
:	NULL
1	NULL
,	NULL
3	NULL
%	NULL
SEA	NULL
(	NULL
1.5	NULL
hr	NULL
)	NULL
;	NULL
2	NULL
,	NULL
3	NULL
%	NULL
SEA	NULL
(	NULL
3	NULL
hr	NULL
)	NULL
;	NULL
3	NULL
,	NULL
3	NULL
%	NULL
SEA	NULL
(	NULL
6	NULL
hr	NULL
)	NULL
;	NULL
4	NULL
,	NULL
1x	NULL
SEA	NULL
(	NULL
1.5	NULL
hr	NULL
)	NULL
;	NULL
5	NULL
,	NULL
1X	NULL
SEA	NULL
(	NULL
3	NULL
hr	NULL
)	NULL
;	NULL
6	NULL
,	NULL
1	NULL
%	NULL
SEA	NULL
(	NULL
6	NULL
hr	NULL
)	NULL
;	NULL
7	NULL
,	NULL
PBS-treated	NULL
control	NULL
.	NULL

One	NULL
of	NULL
three	NULL
similar	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

Immunology	NULL
:	NULL
Sundstedt	NULL
et	NULL
al	NULL
.	NULL

nucleotides	NULL
encoding	NULL
AP-1	NULL
,	NULL
NF-kB	NULL
and	NULL
octamer	NULL
consensus	NULL
motifs	NULL
,	NULL
and	NULL
the	NULL
distal	NULL
NF-AT	NULL
site	NULL
from	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Spleens	NULL
were	NULL
removed	NULL
1	NULL
hr	NULL
after	NULL
the	NULL
last	NULL
SEA	NULL
injection	NULL
,	NULL
preceding	NULL
the	NULL
peak	NULL
time	NULL
point	NULL
for	NULL
IL-2	NULL
mRNA	NULL
expression	NULL
,	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
purified	NULL
CD4*	NULL
spleen	NULL
cells	NULL
.	NULL

AP-1	NULL
binding	NULL
activity	NULL
was	NULL
found	NULL
to	NULL
be	NULL
markedly	NULL
reduced	NULL
in	NULL
anergic	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
3	NULL
%	NULL
SEA	NULL
)	NULL
compared	NULL
to	NULL
activated	NULL
CD4+*	NULL
T	NULL
cells	NULL
(	NULL
1X	NULL
SEA	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
using	NULL
the	NULL
AP-1	NULL
consensus	NULL
sequence	NULL
or	NULL
an	NULL
AP-1	NULL
element	NULL
derived	NULL
from	NULL
the	NULL
murine	NULL
IL-2	NULL
promoter	NULL
(	NULL
17	NULL
)	NULL
,	NULL
although	NULL
the	NULL
latter	NULL
element	NULL
gave	NULL
a	NULL
generally	NULL
weaker	NULL
gel	NULL
shift	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
as	NULL
reported	NULL
in	NULL
earlier	NULL
studies	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Extracts	NULL
from	NULL
PBS-treated	NULL
mice	NULL
contained	NULL
no	NULL
AP-1	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
,	NULL
on	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
was	NULL
induced	NULL
in	NULL
both	NULL
anergic	NULL
and	NULL
activated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
migration	NULL
pattern	NULL
differed	NULL
between	NULL
the	NULL
two	NULL
groups	NULL
.	NULL

Anergic	NULL
cells	NULL
expressed	NULL
mainly	NULL
a	NULL
faster-migrating	NULL
band	NULL
,	NULL
while	NULL
activated	NULL
cells	NULL
contained	NULL
predominantly	NULL
a	NULL
slower-migrating	NULL
band	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

Incubation	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
anergic	NULL
,	NULL
activated	NULL
,	NULL
and	NULL
unstimulated	NULL
cells	NULL
with	NULL
the	NULL
octamer	NULL
element	NULL
showed	NULL
constitutive	NULL
expression	NULL
of	NULL
two	NULL
bands	NULL
,	NULL
most	NULL
likely	NULL
corresponding	NULL
to	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
presence	NULL
of	NULL
NF-AT	NULL
binding	NULL
proteins	NULL
in	NULL
vivo	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
a	NULL
modified	NULL
extraction	NULL
method	NULL
(	NULL
22	NULL
)	NULL
.	NULL

In	NULL
the	NULL
activated	NULL
cells	NULL
(	NULL
1	NULL
%	NULL
SEA	NULL
)	NULL
,	NULL
two	NULL
complexes	NULL
were	NULL
induced	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
,	NULL
indicating	NULL
the	NULL
presence	NULL
of	NULL
NF-AT	NULL
alone	NULL
(	NULL
NF-AT	NULL
,	NULL
)	NULL
and	NULL
NF-AT/Fos-Jun	NULL
as	NULL
described	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
anergic	NULL
cells	NULL
(	NULL
3X	NULL
SEA	NULL
)	NULL
expressed	NULL
a	NULL
slight	NULL
reduction	NULL
A	NULL
<	NULL
``	NULL
oo	NULL
«	NULL
6	NULL
C	NULL
6	NULL
C	NULL
``	NULL
8	NULL
C	NULL
s*	NULL
``	NULL
8	NULL
C	NULL
C	NULL
.C	NULL
(	NULL
58	NULL
>	NULL
xt	NULL
?	NULL

«	NULL
g	NULL
GOG	NULL
o5F	NULL
free	NULL
probe	NULL
-	NULL
>	NULL
1	NULL
2	NULL
3	NULL
4	NULL
Probe	NULL
:	NULL
AP-1	NULL
P	NULL
C	NULL
Extract	NULL
:	NULL
-o	NULL
t	NULL
+o	NULL
+o	NULL
+	NULL
Extract	NULL
:	NULL
Antibody	NULL
:	NULL
~	NULL
Competitor	NULL
:	NULL
NF-AT/AP-1	NULL
-	NULL
>	NULL
NF-ATp	NULL
-	NULL
>	NULL
free	NULL
probe	NULL
-	NULL
>	NULL
1	NULL
2	NULL
3	NULL
4	NULL
6	NULL
Probe	NULL
:	NULL
NF-AT	NULL
Probe	NULL
:	NULL
AP-1	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
981	NULL
of	NULL
the	NULL
lower	NULL
NF-AT	NULL
band	NULL
but	NULL
a	NULL
lack	NULL
of	NULL
the	NULL
upper	NULL
Fos/Jun-containing	NULL
NF-AT	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

The	NULL
identity	NULL
of	NULL
the	NULL
NF-AT	NULL
bands	NULL
observed	NULL
in	NULL
activated	NULL
cells	NULL
was	NULL
further	NULL
defined	NULL
by	NULL
supershift	NULL
analysis	NULL
using	NULL
Abs	NULL
against	NULL
NF-AT	NULL
,	NULL
(	NULL
20	NULL
)	NULL
and	NULL
Fos	NULL
protein	NULL
members	NULL
(	NULL
pan-Fos	NULL
)	NULL
.	NULL

All	NULL
NF-AT	NULL
binding	NULL
activity	NULL
was	NULL
shifted	NULL
by	NULL
NF-AT	NULL
-specific	NULL
Abs	NULL
,	NULL
whereas	NULL
only	NULL
the	NULL
upper	NULL
band	NULL
disappeared	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Fos	NULL
Abs	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
,	NULL
confirming	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
NF-AT/AP-1	NULL
complex	NULL
in	NULL
the	NULL
activated	NULL
cells	NULL
.	NULL

No	NULL
effect	NULL
was	NULL
observed	NULL
with	NULL
control	NULL
IgG	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
was	NULL
verified	NULL
by	NULL
oligonucleotide	NULL
competition	NULL
experiments	NULL
with	NULL
unlabeled	NULL
NF-AT	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
a	NULL
nonbinding	NULL
NF-AT	NULL
mutant	NULL
[	NULL
M3	NULL
(	NULL
23	NULL
)	NULL
]	NULL
.	NULL

The	NULL
NF-AT	NULL
complexes	NULL
were	NULL
blocked	NULL
by	NULL
addition	NULL
of	NULL
the	NULL
NF-AT	NULL
probe	NULL
but	NULL
not	NULL
by	NULL
the	NULL
NF-AT	NULL
M3	NULL
mutant	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
upper	NULL
but	NULL
not	NULL
the	NULL
lower	NULL
complex	NULL
was	NULL
inhibited	NULL
by	NULL
unlabeled	NULL
AP-1	NULL
probe	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
analyze	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
shifted	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
bands	NULL
,	NULL
cross-competition	NULL
experiments	NULL
with	NULL
unlabeled	NULL
oligonucleotides	NULL
were	NULL
performed	NULL
.	NULL

The	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
bands	NULL
were	NULL
completely	NULL
blocked	NULL
with	NULL
unlabeled	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
oligonu-cleotide	NULL
,	NULL
respectively	NULL
,	NULL
but	NULL
not	NULL
with	NULL
the	NULL
nonrelevant	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
the	NULL
protein-DNA	NULL
binding	NULL
is	NULL
specific	NULL
and	NULL
that	NULL
no	NULL
cross-reactivity	NULL
exists	NULL
between	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
proteins	NULL
.	NULL

AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
Are	NULL
Rapidly	NULL
Induced	NULL
in	NULL
Vivo	NULL
.	NULL

To	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
distinct	NULL
expression	NULL
of	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
anergic	NULL
and	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
reflected	NULL
a	NULL
change	NULL
in	NULL
kinetics	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
obtained	NULL
at	NULL
various	NULL
time	NULL
points	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Expression	NULL
of	NULL
AP-1	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
NF-AT	NULL
,	NULL
and	NULL
Oct	NULL
binding	NULL
proteins	NULL
after	NULL
SEA	NULL
treatment	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Mice	NULL
were	NULL
treated	NULL
one	NULL
or	NULL
three	NULL
times	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
SEA	NULL
or	NULL
vehicle	NULL
(	NULL
PBS	NULL
)	NULL
,	NULL
and	NULL
spleens	NULL
were	NULL
removed	NULL
1	NULL
hr	NULL
after	NULL
the	NULL
last	NULL
injection	NULL
.	NULL

Nuclear	NULL
protein	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
and	NULL
used	NULL
for	NULL
gel-shift	NULL
analysis	NULL
with	NULL
*P-labeled	NULL
oligonucleotides	NULL
specific	NULL
for	NULL
AP-1	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
Oct	NULL
,	NULL
and	NULL
NF-AT	NULL
sites	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Supershift	NULL
analysis	NULL
of	NULL
the	NULL
NF-AT	NULL
binding	NULL
complexes	NULL
.	NULL

Nuclear	NULL
extract	NULL
from	NULL
spleen	NULL
cells	NULL
of	NULL
mice	NULL
treated	NULL
once	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
SEA	NULL
was	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
antisera	NULL
directed	NULL
against	NULL
NF-AT	NULL
,	NULL
,	NULL
pan-Fos	NULL
members	NULL
(	NULL
Fos	NULL
)	NULL
,	NULL
or	NULL
control	NULL
serum	NULL
before	NULL
addition	NULL
of	NULL
labeled	NULL
NF-AT	NULL
probe	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Cross-competition	NULL
of	NULL
AP-1	NULL
vs.	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
.	NULL

Nuclear	NULL
extract	NULL
from	NULL
CD4*	NULL
T	NULL
cells	NULL
was	NULL
incubated	NULL
with	NULL
50-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
competitors	NULL
for	NULL
15	NULL
min	NULL
before	NULL
addition	NULL
of	NULL
labeled	NULL
DNA	NULL
.	NULL

One	NULL
of	NULL
three	NULL
similar	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

982	NULL
Immunology	NULL
:	NULL
Sundstedt	NULL
et	NULL
al	NULL
.	NULL

after	NULL
in	NULL
vivo	NULL
SEA	NULL
treatment	NULL
.	NULL

AP-1	NULL
activity	NULL
was	NULL
found	NULL
to	NULL
be	NULL
induced	NULL
after	NULL
15	NULL
min	NULL
,	NULL
increased	NULL
to	NULL
maximum	NULL
at	NULL
1	NULL
hr	NULL
,	NULL
and	NULL
remained	NULL
detectable	NULL
up	NULL
to	NULL
at	NULL
least	NULL
4	NULL
hr	NULL
after	NULL
SEA	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
AP-1	NULL
binding	NULL
activity	NULL
was	NULL
strongly	NULL
reduced	NULL
in	NULL
anergic	NULL
cells	NULL
at	NULL
all	NULL
time	NULL
points	NULL
studied	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
.	NULL

The	NULL
upper	NULL
NF-	NULL
«	NULL
B	NULL
band	NULL
(	NULL
B1	NULL
)	NULL
was	NULL
present	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
after	NULL
15	NULL
min	NULL
and	NULL
remained	NULL
the	NULL
dominating	NULL
band	NULL
up	NULL
to	NULL
4	NULL
hr	NULL
after	NULL
SEA	NULL
injection	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

A	NULL
minor	NULL
component	NULL
of	NULL
a	NULL
lower	NULL
migrating	NULL
band	NULL
(	NULL
B2	NULL
)	NULL
was	NULL
seen	NULL
in	NULL
activated	NULL
cells	NULL
at	NULL
4	NULL
hr	NULL
.	NULL

In	NULL
the	NULL
anergic	NULL
cells	NULL
,	NULL
the	NULL
lower	NULL
band	NULL
became	NULL
visible	NULL
after	NULL
15	NULL
min	NULL
and	NULL
constituted	NULL
the	NULL
major	NULL
band	NULL
after	NULL
1-4	NULL
hr	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

A	NULL
minor	NULL
component	NULL
of	NULL
the	NULL
upper	NULL
band	NULL
(	NULL
B1	NULL
)	NULL
was	NULL
indicated	NULL
at	NULL
15	NULL
min	NULL
and	NULL
1	NULL
hr	NULL
in	NULL
anergic	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Low	NULL
Expression	NULL
of	NULL
p50-p65	NULL
Heterodimers	NULL
in	NULL
Anergic	NULL
CD4+*	NULL
T	NULL
Cells	NULL
.	NULL

To	NULL
identify	NULL
which	NULL
components	NULL
of	NULL
the	NULL
Rel	NULL
family	NULL
bind	NULL
as	NULL
upper	NULL
or	NULL
lower	NULL
bands	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
element	NULL
,	NULL
we	NULL
used	NULL
specific	NULL
Abs	NULL
to	NULL
p50	NULL
,	NULL
p65	NULL
,	NULL
and	NULL
c-Rel	NULL
.	NULL

Supershift	NULL
analysis	NULL
revealed	NULL
that	NULL
the	NULL
lower	NULL
NF-	NULL
«	NULL
B	NULL
band	NULL
,	NULL
the	NULL
main	NULL
constituent	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
anergic	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
was	NULL
p50-p50	NULL
homodimers	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

The	NULL
upper	NULL
band	NULL
,	NULL
which	NULL
is	NULL
the	NULL
major	NULL
NF-	NULL
«	NULL
B	NULL
shift	NULL
in	NULL
nuclear	NULL
extract	NULL
of	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
was	NULL
shown	NULL
to	NULL
represent	NULL
p50-p65	NULL
heterodimers	NULL
,	NULL
since	NULL
it	NULL
was	NULL
shifted	NULL
by	NULL
both	NULL
p50	NULL
and	NULL
p65	NULL
Abs	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

No	NULL
c-Rel	NULL
component	NULL
was	NULL
found	NULL
in	NULL
either	NULL
of	NULL
the	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

CD4*	NULL
T	NULL
cells	NULL
from	NULL
untreated	NULL
mice	NULL
contained	NULL
A	NULL
CD4+	NULL
,	NULL
3xSEA	NULL
CD4+	NULL
,	NULL
1xSEA	NULL
Time	NULL
(	NULL
min	NULL
)	NULL
:	NULL
-	NULL
0	NULL
5	NULL
15	NULL
60	NULL
240	NULL
-	NULL
0	NULL
5	NULL
15	NULL
60	NULL
240	NULL
®	NULL
#	NULL
free	NULL
probe	NULL
-	NULL
>	NULL
1	NULL
2	NULL
3	NULL
4	NULL
56	NULL
7	NULL
.	NULL

B	NULL
9:10	NULL
11	NULL
12	NULL
Probe	NULL
:	NULL
AP-1	NULL
AP-1	NULL
B	NULL
CD4+	NULL
,	NULL
3xSEA	NULL
CD4+	NULL
,	NULL
1xSEA	NULL
Time	NULL
(	NULL
min	NULL
)	NULL
:	NULL
-	NULL
0	NULL
15	NULL
60	NULL
120	NULL
240	NULL
-	NULL
0	NULL
15	NULL
60	NULL
120	NULL
240	NULL
ne	NULL
coal	NULL
calmed	NULL
came	NULL
w	NULL
»	NULL
woman	NULL
%	NULL
B1	NULL
-	NULL
>	NULL
B2	NULL
-	NULL
>	NULL
free	NULL
probe	NULL
-	NULL
>	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
.	NULL

°-B	NULL
9	NULL
10	NULL
11	NULL
12	NULL
Probe	NULL
:	NULL
NF-kB	NULL
NF-kB	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Kinetics	NULL
of	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
expression	NULL
after	NULL
SEA	NULL
treatment	NULL
.	NULL

Mice	NULL
were	NULL
treated	NULL
one	NULL
or	NULL
three	NULL
times	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
SEA	NULL
,	NULL
and	NULL
spleens	NULL
were	NULL
removed	NULL
at	NULL
different	NULL
time	NULL
points	NULL
after	NULL
the	NULL
last	NULL
injection	NULL
.	NULL

Nuclear	NULL
protein	NULL
extracts	NULL
made	NULL
from	NULL
purified	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
used	NULL
for	NULL
gel-shift	NULL
analysis	NULL
with	NULL
3°P-labeled	NULL
oligonucleotides	NULL
specific	NULL
for	NULL
AP-1	NULL
(	NULL
4	NULL
)	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
B	NULL
)	NULL
.	NULL

Arrows	NULL
indicate	NULL
positions	NULL
of	NULL
specific	NULL
DNA-protein	NULL
complexes	NULL
.	NULL

One	NULL
of	NULL
two	NULL
similar	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
CD4+	NULL
,	NULL
3xSEA	NULL
CD4+	NULL
,	NULL
1xSEA	NULL
extract	NULL
:	NULL
to	NULL
$	NULL
o	NULL
to	NULL
#	NULL
1004	NULL
$	NULL
0	NULL
40	NULL
+	NULL
+	NULL
antibody	NULL
:	NULL
-	NULL
-_	NULL
P	NULL
P	NULL
#	NULL
-	NULL
8	NULL
$	NULL
wite	NULL
p50-p65	NULL
-	NULL
>	NULL
p50-p50	NULL
-	NULL
>	NULL
1	NULL
~2.593°	NULL
4	NULL
5	NULL
6	NULL
7-	NULL
8	NULL
9	NULL
Probe	NULL
:	NULL
NF-kB	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

-	NULL
Supershift	NULL
analysis	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
complexes	NULL
.	NULL

Mice	NULL
were	NULL
treated	NULL
one	NULL
or	NULL
three	NULL
times	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
SEA	NULL
,	NULL
and	NULL
spleens	NULL
were	NULL
removed	NULL
1	NULL
hr	NULL
after	NULL
the	NULL
last	NULL
injection	NULL
.	NULL

Nuclear	NULL
protein	NULL
extracts	NULL
made	NULL
from	NULL
purified	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
used	NULL
for	NULL
gel-shift	NULL
analysis	NULL
with	NULL
oligonucleotides	NULL
specific	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
anti-p50	NULL
(	NULL
p50	NULL
)	NULL
,	NULL
anti-p65	NULL
(	NULL
p65	NULL
)	NULL
,	NULL
or	NULL
anti-c-Rel	NULL
(	NULL
c-Rel	NULL
)	NULL
subunit-specific	NULL
Abs	NULL
.	NULL

One	NULL
of	NULL
three	NULL
similar	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

very	NULL
low	NULL
levels	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
,	NULL
shown	NULL
by	NULL
supershift	NULL
analysis	NULL
to	NULL
be	NULL
solely	NULL
p50-p50	NULL
homodimers	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

AP-1	NULL
Composition	NULL
Is	NULL
Not	NULL
Significantly	NULL
Altered	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
AP-1	NULL
binding	NULL
components	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
anergic	NULL
and	NULL
activated	NULL
T-helper	NULL
cells	NULL
,	NULL
we	NULL
performed	NULL
supershift	NULL
analyses	NULL
with	NULL
antisera	NULL
to	NULL
a	NULL
panel	NULL
of	NULL
different	NULL
Fos	NULL
and	NULL
Jun	NULL
members	NULL
.	NULL

The	NULL
1-hr	NULL
extracts	NULL
from	NULL
both	NULL
anergic	NULL
and	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
exhibited	NULL
the	NULL
same	NULL
pattern	NULL
of	NULL
AP-1	NULL
components	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

c-Fos	NULL
was	NULL
shown	NULL
to	NULL
constitute	NULL
the	NULL
major	NULL
Fos	NULL
protein	NULL
in	NULL
these	NULL
extracts	NULL
,	NULL
and	NULL
substantial	NULL
amounts	NULL
of	NULL
JunB	NULL
and	NULL
JunD	NULL
were	NULL
also	NULL
present	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Addition	NULL
of	NULL
antisera	NULL
against	NULL
Fra-2	NULL
somewhat	NULL
reduced	NULL
the	NULL
bands	NULL
in	NULL
activated	NULL
and	NULL
anergic	NULL
cells	NULL
,	NULL
indicating	NULL
participation	NULL
of	NULL
this	NULL
protein	NULL
in	NULL
the	NULL
AP-1	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

This	NULL
was	NULL
not	NULL
due	NULL
to	NULL
unspecific	NULL
proteolytic	NULL
activity	NULL
,	NULL
since	NULL
the	NULL
antisera	NULL
did	NULL
not	NULL
influence	NULL
gel	NULL
shift	NULL
of	NULL
an	NULL
unrelated	NULL
nuclear	NULL
factor	NULL
(	NULL
data	NULL
not	NULL
CD4+	NULL
,	NULL
3xSEA	NULL
CD4+	NULL
,	NULL
1xSEA	NULL
.	NULL

P	NULL
P	NULL
J	NULL
.J	NULL
.	NULL

*	NULL
``	NULL
.	NULL

>	NULL
_	NULL
G	NULL
$	NULL
5.8	NULL
.	NULL
``	NULL

.	NULL

*	NULL
antibody	NULL
:	NULL
-	NULL
-	NULL
y	NULL
``	NULL
$	NULL
y9Y	NULL
[	NULL
CCC	NULL
-	NULL
-	NULL
5	NULL
``	NULL
pUC	NULL
(	NULL
C	NULL
1	NULL
2	NULL
``	NULL
``	NULL
3	NULL
45	NULL
6.97	NULL
8	NULL
1	NULL
4506	NULL
7	NULL
8	NULL
Probe	NULL
:	NULL
AP-1	NULL
AP-1	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

-	NULL
Supershift	NULL
analysis	NULL
of	NULL
AP-1	NULL
binding	NULL
complexes	NULL
.	NULL

Mice	NULL
were	NULL
treated	NULL
one	NULL
or	NULL
three	NULL
times	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
SEA	NULL
,	NULL
and	NULL
spleens	NULL
were	NULL
removed	NULL
1	NULL
hr	NULL
after	NULL
the	NULL
last	NULL
injection	NULL
.	NULL

Nuclear	NULL
protein	NULL
extracts	NULL
made	NULL
from	NULL
purified	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
used	NULL
for	NULL
gel-shift	NULL
analysis	NULL
with	NULL
2P-labeled	NULL
oligonucleotides	NULL
specific	NULL
for	NULL
AP-1	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
anti-c-Jun	NULL
(	NULL
c-Jun	NULL
)	NULL
,	NULL
anti-JunB	NULL
(	NULL
JunB	NULL
)	NULL
,	NULL
anti-JunD	NULL
(	NULL
JunD	NULL
)	NULL
,	NULL
anti-c-Fos	NULL
(	NULL
c-Fos	NULL
)	NULL
,	NULL
anti-Fra-1	NULL
(	NULL
Fra-1	NULL
)	NULL
,	NULL
or	NULL
anti-Fra-2	NULL
(	NULL
Fra-2	NULL
)	NULL
subunit-specific	NULL
Abs	NULL
.	NULL

One	NULL
of	NULL
three	NULL
similar	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

Immunology	NULL
:	NULL
Sundstedt	NULL
et	NULL
al	NULL
.	NULL

shown	NULL
)	NULL
.	NULL

No	NULL
effect	NULL
of	NULL
antisera	NULL
against	NULL
c-Jun	NULL
and	NULL
Fra-l	NULL
was	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
,	NULL
even	NULL
though	NULL
these	NULL
Abs	NULL
were	NULL
shown	NULL
to	NULL
be	NULL
reactive	NULL
in	NULL
supershifts	NULL
using	NULL
a	NULL
control	NULL
extract	NULL
from	NULL
phorbol	NULL
ester-stimulated	NULL
mouse	NULL
fibroblasts	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DISCUSSION	NULL
In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
the	NULL
failure	NULL
of	NULL
SAg	NULL
anergized	NULL
T-helper	NULL
cells	NULL
to	NULL
produce	NULL
IL-2	NULL
in	NULL
vivo	NULL
correlates	NULL
with	NULL
perturbed	NULL
expression	NULL
of	NULL
AP-1	NULL
,	NULL
AP-l-containing	NULL
NF-AT	NULL
,	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
transcription	NULL
factors	NULL
.	NULL

Resting	NULL
CD4*	NULL
T	NULL
cells	NULL
contained	NULL
low	NULL
levels	NULL
of	NULL
p50-p50	NULL
NF-	NULL
«	NULL
B	NULL
homodimer	NULL
and	NULL
did	NULL
not	NULL
express	NULL
AP-1	NULL
proteins	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
SEA-activated	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
were	NULL
rapidly	NULL
induced	NULL
to	NULL
express	NULL
large	NULL
amounts	NULL
of	NULL
p50-p65	NULL
NF-kB	NULL
heterodimers	NULL
,	NULL
AP-1	NULL
proteins	NULL
,	NULL
and	NULL
the	NULL
two	NULL
NF-AT	NULL
binding	NULL
complexes	NULL
.	NULL

These	NULL
data	NULL
are	NULL
in	NULL
accordance	NULL
with	NULL
earlier	NULL
in	NULL
vitro	NULL
studies	NULL
on	NULL
murine	NULL
T-cell	NULL
clones	NULL
and	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
.	NULL

The	NULL
in	NULL
vivo	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
heterodimer	NULL
,	NULL
NF-AT	NULL
,	NULL
and	NULL
AP-1	NULL
was	NULL
extremely	NULL
rapid	NULL
compared	NULL
to	NULL
earlier	NULL
in	NULL
vitro	NULL
reported	NULL
characteristics	NULL
(	NULL
27	NULL
)	NULL
,	NULL
implicating	NULL
a	NULL
coordinated	NULL
and	NULL
very	NULL
rapid	NULL
transition	NULL
from	NULL
induction	NULL
of	NULL
nuclear	NULL
transcription	NULL
factors	NULL
,	NULL
transcription	NULL
,	NULL
translation	NULL
,	NULL
and	NULL
IL-2	NULL
secretion	NULL
in	NULL
vivo	NULL
.	NULL

A	NULL
marked	NULL
decrease	NULL
of	NULL
AP-1	NULL
binding	NULL
proteins	NULL
and	NULL
a	NULL
changed	NULL
migration	NULL
pattern	NULL
of	NULL
the	NULL
NF-kB	NULL
binding	NULL
complex	NULL
were	NULL
seen	NULL
in	NULL
anergic	NULL
CD4*	NULL
T	NULL
cells	NULL
at	NULL
15	NULL
min	NULL
to	NULL
at	NULL
least	NULL
4	NULL
hr	NULL
after	NULL
injection	NULL
of	NULL
SEA	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
a	NULL
faster-migrating	NULL
octamer	NULL
binding	NULL
complex	NULL
,	NULL
characterized	NULL
as	NULL
Oct-2	NULL
by	NULL
supershift	NULL
analysis	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
was	NULL
more	NULL
pronounced	NULL
in	NULL
anergic	NULL
compared	NULL
to	NULL
resting	NULL
or	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

The	NULL
changed	NULL
Oct-1	NULL
/	NULL
Oct-2	NULL
ratio	NULL
might	NULL
be	NULL
important	NULL
since	NULL
functional	NULL
differences	NULL
between	NULL
these	NULL
factors	NULL
have	NULL
been	NULL
demonstrated	NULL
(	NULL
28	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
models	NULL
of	NULL
anergy	NULL
have	NULL
clearly	NULL
established	NULL
an	NULL
association	NULL
between	NULL
repressed	NULL
IL-2	NULL
gene	NULL
expression	NULL
and	NULL
the	NULL
non-responsive	NULL
state	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
Kang	NULL
et	NULL
al	NULL
.	NULL

(	NULL
17	NULL
)	NULL
reported	NULL
diminished	NULL
levels	NULL
of	NULL
AP-1	NULL
but	NULL
normal	NULL
levels	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
NF-IL2A	NULL
(	NULL
octamer	NULL
element	NULL
)	NULL
,	NULL
and	NULL
NF-AT	NULL
in	NULL
a	NULL
T-cell	NULL
clone	NULL
rendered	NULL
anergic	NULL
by	NULL
TCR	NULL
stimulation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
costimu-lation	NULL
(	NULL
17	NULL
)	NULL
.	NULL

The	NULL
composition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
proteins	NULL
was	NULL
not	NULL
examined	NULL
in	NULL
this	NULL
study	NULL
(	NULL
17	NULL
)	NULL
.	NULL

However	NULL
,	NULL
transfection	NULL
of	NULL
the	NULL
T-cell	NULL
clone	NULL
and	NULL
reporter	NULL
gene	NULL
experiments	NULL
indicated	NULL
that	NULL
an	NULL
IL-2/	NULL
NF-	NULL
«	NULL
B	NULL
promoter	NULL
was	NULL
slightly	NULL
less	NULL
efficiently	NULL
driven	NULL
in	NULL
the	NULL
anergic	NULL
T	NULL
cells	NULL
compared	NULL
to	NULL
normal	NULL
T	NULL
cells	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Further	NULL
experiments	NULL
are	NULL
required	NULL
to	NULL
evaluate	NULL
the	NULL
relative	NULL
importance	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
on	NULL
the	NULL
response	NULL
of	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
anergized	NULL
T	NULL
cells	NULL
,	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
transcription	NULL
factors	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
several	NULL
important	NULL
aspects	NULL
of	NULL
T-cell	NULL
development	NULL
and	NULL
activation	NULL
(	NULL
12	NULL
,	NULL
29	NULL
)	NULL
.	NULL

Mutations	NULL
in	NULL
the	NULL
AP-1	NULL
proximal	NULL
site	NULL
present	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
greatly	NULL
diminished	NULL
or	NULL
abolished	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
8	NULL
,	NULL
24	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
overexpression	NULL
of	NULL
c-Fos	NULL
in	NULL
transgenic	NULL
mice	NULL
accelerated	NULL
in	NULL
vitro	NULL
release	NULL
of	NULL
IL-2	NULL
by	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
30	NULL
)	NULL
,	NULL
which	NULL
underlines	NULL
the	NULL
central	NULL
importance	NULL
of	NULL
AP-1	NULL
in	NULL
regulating	NULL
IL-2	NULL
production	NULL
.	NULL

Furthermore	NULL
,	NULL
regulatory	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
have	NULL
been	NULL
found	NULL
in	NULL
several	NULL
cytokine	NULL
gene	NULL
promoters	NULL
,	NULL
including	NULL
IL-6	NULL
and	NULL
TNF-	NULL
«	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
TNF	NULL
production	NULL
is	NULL
also	NULL
down-regulated	NULL
in	NULL
SEA	NULL
anergized	NULL
CD4*	NULL
T	NULL
cells	NULL
in	NULL
vivo	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Supershift	NULL
analyses	NULL
of	NULL
the	NULL
AP-1	NULL
complexes	NULL
demonstrated	NULL
that	NULL
activated	NULL
T	NULL
cells	NULL
expressed	NULL
substantial	NULL
amounts	NULL
of	NULL
JunB	NULL
,	NULL
JunD	NULL
,	NULL
and	NULL
c-Fos	NULL
and	NULL
minor	NULL
amounts	NULL
of	NULL
Fra-2	NULL
.	NULL

Moreover	NULL
,	NULL
supershift	NULL
with	NULL
pan-Fos	NULL
family	NULL
antisera	NULL
completely	NULL
abrogated	NULL
the	NULL
shift	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
all	NULL
AP-1	NULL
DNA	NULL
binding	NULL
activity	NULL
is	NULL
related	NULL
to	NULL
Fos-Jun	NULL
heterodimers	NULL
,	NULL
which	NULL
have	NULL
a	NULL
notably	NULL
higher	NULL
DNA	NULL
binding	NULL
affinity	NULL
than	NULL
Jun-Jun	NULL
homodimers	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
Rincon	NULL
and	NULL
Flavell	NULL
(	NULL
33	NULL
)	NULL
demonstrated	NULL
that	NULL
mouse	NULL
T	NULL
cells	NULL
activated	NULL
with	NULL
anti-CD3	NULL
Ab	NULL
in	NULL
vitro	NULL
expressed	NULL
JunB	NULL
,	NULL
c-Jun	NULL
,	NULL
Fra-2	NULL
,	NULL
and	NULL
FosB	NULL
but	NULL
not	NULL
Fra-1	NULL
or	NULL
JunD	NULL
in	NULL
the	NULL
AP-1	NULL
complex	NULL
.	NULL

The	NULL
discrepancy	NULL
concerning	NULL
JunD	NULL
is	NULL
unclear	NULL
,	NULL
but	NULL
it	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
JunD	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
a	NULL
stronger	NULL
transcriptional	NULL
activator	NULL
than	NULL
JunB	NULL
(	NULL
10	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
SAg-activated	NULL
T	NULL
cells	NULL
express	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
983	NULL
a	NULL
favorable	NULL
AP-1	NULL
composition	NULL
for	NULL
driving	NULL
IL-2	NULL
gene	NULL
expression	NULL
.	NULL

Using	NULL
TG	NULL
mice	NULL
that	NULL
expressed	NULL
an	NULL
AP-1	NULL
driven	NULL
reporter	NULL
gene	NULL
,	NULL
Rincon	NULL
and	NULL
Flavell	NULL
(	NULL
33	NULL
)	NULL
reported	NULL
a	NULL
lack	NULL
of	NULL
correlation	NULL
between	NULL
AP-1	NULL
DNA	NULL
binding	NULL
and	NULL
IL-2	NULL
production	NULL
.	NULL

In	NULL
our	NULL
studies	NULL
,	NULL
however	NULL
,	NULL
there	NULL
was	NULL
a	NULL
strong	NULL
correlation	NULL
between	NULL
AP-1	NULL
expression	NULL
and	NULL
the	NULL
ability	NULL
to	NULL
express	NULL
IL-2	NULL
at	NULL
the	NULL
mRNA	NULL
and	NULL
protein	NULL
levels	NULL
.	NULL

Indeed	NULL
,	NULL
reduced	NULL
AP-1	NULL
levels	NULL
were	NULL
also	NULL
found	NULL
in	NULL
in	NULL
vitro	NULL
anergized	NULL
T	NULL
cells	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Whether	NULL
these	NULL
discrepancies	NULL
reflect	NULL
differences	NULL
in	NULL
the	NULL
response	NULL
to	NULL
stimulation	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
or	NULL
an	NULL
abnormal	NULL
regulation	NULL
of	NULL
the	NULL
AP-1	NULL
promoter	NULL
transgene	NULL
needs	NULL
to	NULL
be	NULL
further	NULL
addressed	NULL
.	NULL

NF-AT	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
be	NULL
induced	NULL
in	NULL
CD4*	NULL
T-helper	NULL
1	NULL
clones	NULL
stimulated	NULL
through	NULL
the	NULL
TCR-CD3	NULL
complex	NULL
and	NULL
to	NULL
be	NULL
required	NULL
for	NULL
IL-2	NULL
gene	NULL
induction	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Factors	NULL
binding	NULL
to	NULL
the	NULL
NF-AT	NULL
motif	NULL
have	NULL
previously	NULL
been	NULL
reported	NULL
to	NULL
consist	NULL
of	NULL
two	NULL
components	NULL
:	NULL
NF-AT	NULL
,	NULL
,	NULL
which	NULL
preexists	NULL
in	NULL
the	NULL
cytosol	NULL
,	NULL
and	NULL
a	NULL
nuclear	NULL
AP-1-associated	NULL
complex	NULL
,	NULL
which	NULL
contains	NULL
translocated	NULL
NF-AT	NULL
,	NULL
protein	NULL
(	NULL
18	NULL
)	NULL
.	NULL

We	NULL
now	NULL
demonstrate	NULL
induction	NULL
of	NULL
both	NULL
NF-AT	NULL
,	NULL
and	NULL
NF-AT/AP-1	NULL
factors	NULL
in	NULL
activated	NULL
cells	NULL
,	NULL
while	NULL
the	NULL
anergic	NULL
cells	NULL
predominantly	NULL
expressed	NULL
the	NULL
NF-AT	NULL
,	NULL
component	NULL
alone	NULL
.	NULL

These	NULL
results	NULL
imply	NULL
that	NULL
lack	NULL
of	NULL
the	NULL
NF-AT/AP-1	NULL
complex	NULL
in	NULL
anergic	NULL
cells	NULL
might	NULL
be	NULL
secondary	NULL
to	NULL
modulation	NULL
of	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
.	NULL

Interestingly	NULL
,	NULL
mutations	NULL
in	NULL
the	NULL
NF-AT	NULL
site	NULL
that	NULL
prevented	NULL
association	NULL
of	NULL
Fos	NULL
and	NULL
Jun	NULL
with	NULL
NF-AT	NULL
,	NULL
abolished	NULL
the	NULL
function	NULL
of	NULL
this	NULL
site	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
34	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
AP-1	NULL
component	NULL
in	NULL
the	NULL
NF-AT	NULL
complex	NULL
is	NULL
essential	NULL
for	NULL
transcription	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
down-regulation	NULL
of	NULL
NF-AT/AP-1	NULL
in	NULL
anergized	NULL
T	NULL
cells	NULL
further	NULL
contributes	NULL
to	NULL
defective	NULL
IL-2	NULL
production	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
two	NULL
different	NULL
forms	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
were	NULL
detected	NULL
in	NULL
activated	NULL
and	NULL
anergic	NULL
CD4*	NULL
T	NULL
cells	NULL
at	NULL
time	NULL
points	NULL
relevant	NULL
for	NULL
IL-2	NULL
mRNA	NULL
and	NULL
protein	NULL
production	NULL
.	NULL

Kinetic	NULL
analysis	NULL
of	NULL
the	NULL
NF-kB	NULL
response	NULL
demonstrated	NULL
that	NULL
p50-p65	NULL
was	NULL
induced	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
after	NULL
5-15	NULL
min	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
which	NULL
most	NULL
likely	NULL
reflects	NULL
release	NULL
of	NULL
preformed	NULL
p50-p65	NULL
from	NULL
I	NULL
«	NULL
B	NULL
inhibitors	NULL
(	NULL
35	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
p50-p65	NULL
after	NULL
1-2	NULL
hr	NULL
of	NULL
activation	NULL
may	NULL
reflect	NULL
de	NULL
novo	NULL
synthesized	NULL
p65	NULL
protein	NULL
.	NULL

Anergized	NULL
CD4*	NULL
T	NULL
cells	NULL
expressed	NULL
large	NULL
amounts	NULL
of	NULL
p50-p50	NULL
homodimers	NULL
throughout	NULL
the	NULL
4-hr	NULL
observation	NULL
period	NULL
,	NULL
while	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
expressed	NULL
the	NULL
homodimer	NULL
only	NULL
after	NULL
4	NULL
hr	NULL
of	NULL
activation	NULL
in	NULL
vivo	NULL
.	NULL

The	NULL
delayed	NULL
induction	NULL
of	NULL
inhibitory	NULL
p50-p50	NULL
protein	NULL
may	NULL
represent	NULL
a	NULL
normal	NULL
regulatory	NULL
feature	NULL
of	NULL
IL-2	NULL
production	NULL
,	NULL
since	NULL
only	NULL
low	NULL
levels	NULL
of	NULL
IL-2	NULL
mRNA	NULL
and	NULL
protein	NULL
were	NULL
found	NULL
at	NULL
corresponding	NULL
time	NULL
points	NULL
.	NULL

In	NULL
line	NULL
with	NULL
this	NULL
finding	NULL
,	NULL
it	NULL
has	NULL
been	NULL
demonstrated	NULL
in	NULL
several	NULL
experimental	NULL
systems	NULL
that	NULL
p50-p50	NULL
homodimers	NULL
lack	NULL
transcriptional	NULL
activity	NULL
and	NULL
instead	NULL
occupy	NULL
cognate	NULL
NF-kB	NULL
binding	NULL
sites	NULL
and	NULL
prevent	NULL
transactivation	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

A	NULL
recent	NULL
study	NULL
showed	NULL
a	NULL
correlation	NULL
between	NULL
p50-p50	NULL
induction	NULL
and	NULL
lack	NULL
of	NULL
TNF	NULL
production	NULL
during	NULL
LPS	NULL
tolerance	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
this	NULL
suggests	NULL
that	NULL
the	NULL
balance	NULL
between	NULL
NF-kB	NULL
p50-p65	NULL
heterodimers	NULL
and	NULL
pS50-p50	NULL
homodimers	NULL
may	NULL
be	NULL
a	NULL
central	NULL
mechanism	NULL
for	NULL
regulating	NULL
cytokine	NULL
production	NULL
in	NULL
vivo	NULL
.	NULL

We	NULL
thank	NULL
Ms.	NULL
Karin	NULL
Hedse	NULL
,	NULL
Kristina	NULL
Behm	NULL
,	NULL
Christa	NULL
Borgstrom	NULL
,	NULL
Mr.	NULL
Jan	NULL
Nilsson	NULL
,	NULL
and	NULL
Per-Anders	NULL
Bertilsson	NULL
for	NULL
skillful	NULL
technical	NULL
assistance	NULL
and	NULL
Dr.	NULL
C.	NULL
Verweij	NULL
(	NULL
Leiden	NULL
,	NULL
The	NULL
Netherlands	NULL
)	NULL
and	NULL
Dr.	NULL
A.	NULL
Rao	NULL
(	NULL
Boston	NULL
)	NULL
for	NULL
scientific	NULL
advice	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Swedish	NULL
Cancer	NULL
Society	NULL
and	NULL
the	NULL
Swedish	NULL
Medical	NULL
Research	NULL
Council	NULL
.	NULL

1	NULL
.	NULL

Marrack	NULL
,	NULL
P.	NULL
&	NULL
Kappler	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Science	NULL
248	NULL
,	NULL
705-711	NULL
.	NULL

2	NULL
.	NULL

Choi	NULL
,	NULL
Y.	NULL
,	NULL
Herman	NULL
,	NULL
A.	NULL
,	NULL
GiGiusto	NULL
,	NULL
T.	NULL
,	NULL
Wade	NULL
,	NULL
T.	NULL
,	NULL
Marrack	NULL
,	NULL
P.	NULL
&	NULL
Kappler	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
34	NULL
,	NULL
471-473	NULL
.	NULL

3	NULL
.	NULL

Dohisten	NULL
,	NULL
M.	NULL
,	NULL
Bjorklund	NULL
,	NULL
M.	NULL
,	NULL
Sundstedt	NULL
,	NULL
A.	NULL
,	NULL
Hedlund	NULL
,	NULL
G.	NULL
,	NULL
San-som	NULL
,	NULL
D.	NULL
&	NULL
Kalland	NULL
,	NULL
T.	NULL
(	NULL
1993	NULL
)	NULL
Immunology	NULL
79	NULL
,	NULL
520-527	NULL
.	NULL

4	NULL
.	NULL

-	NULL
Sundstedt	NULL
,	NULL
A.	NULL
,	NULL
Dohlsten	NULL
,	NULL
M.	NULL
,	NULL
Hedlund	NULL
,	NULL
G.	NULL
,	NULL
Héidén	NULL
,	NULL
I.	NULL
,	NULL
Bjorklund	NULL
,	NULL
M.	NULL
&	NULL
Kalland	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Immunology	NULL
82	NULL
,	NULL
117-125	NULL
.	NULL

5	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
243	NULL
,	NULL
355-361	NULL
.	NULL

984	NULL
13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

Immunology	NULL
:	NULL
Sundstedt	NULL
et	NULL
al	NULL
.	NULL

Serfling	NULL
,	NULL
E.	NULL
,	NULL
Barthelmas	NULL
,	NULL
R.	NULL
,	NULL
Pfeuffer	NULL
,	NULL
I.	NULL
,	NULL
Schenk	NULL
,	NULL
B.	NULL
,	NULL
Zarius	NULL
,	NULL
S.	NULL
,	NULL
Swoboda	NULL
,	NULL
R.	NULL
,	NULL
Mercurio	NULL
,	NULL
F.	NULL
&	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

8	NULL
,	NULL
465-473	NULL
.	NULL

Umlauf	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
Beverly	NULL
,	NULL
B.	NULL
,	NULL
Kang	NULL
,	NULL
S.-M.	NULL
,	NULL
Brorson	NULL
,	NULL
K.	NULL
,	NULL
Tran	NULL
,	NULL
A.-C.	NULL
&	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1993	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

133	NULL
,	NULL
177-197	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Shaw	NULL
,	NULL
J.-P.	NULL
,	NULL
Bush	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Replogle	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Bel-agaje	NULL
,	NULL
R.	NULL
&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
1715-1724	NULL
.	NULL

Radler-Pohl	NULL
,	NULL
A.	NULL
,	NULL
Gebel	NULL
,	NULL
S.	NULL
,	NULL
Sachsenmaier	NULL
,	NULL
C.	NULL
,	NULL
Konig	NULL
,	NULL
H.	NULL
,	NULL
Kramer	NULL
,	NULL
M.	NULL
,	NULL
Oehler	NULL
,	NULL
T.	NULL
,	NULL
Streile	NULL
,	NULL
M.	NULL
,	NULL
Ponta	NULL
,	NULL
H.	NULL
,	NULL
Rapp	NULL
,	NULL
U	NULL
.	NULL

&	NULL
Rahmsdorf	NULL
,	NULL
H.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Ann	NULL
.	NULL

N.Y.	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
684	NULL
,	NULL
127-148	NULL
.	NULL

Ryder	NULL
,	NULL
K.	NULL
,	NULL
Lanahan	NULL
,	NULL
A.	NULL
,	NULL
Perez-Albuerne	NULL
,	NULL
E.	NULL
&	NULL
Nathans	NULL
,	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86	NULL
,	NULL
1500-1503	NULL
.	NULL

Ryseck	NULL
,	NULL
R.-P.	NULL
&	NULL
Bravo	NULL
,	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Oncogene	NULL
6	NULL
,	NULL
533-542	NULL
.	NULL

Kang	NULL
,	NULL
S.-M.	NULL
,	NULL
Tran	NULL
,	NULL
A.-C.	NULL
,	NULL
Grilli	NULL
,	NULL
M.	NULL
&	NULL
Lenardo	NULL
,	NULL
M.J.	NULL
(	NULL
1992	NULL
)	NULL
Science	NULL
256	NULL
,	NULL
1452-1456	NULL
.	NULL

Schmitz	NULL
,	NULL
M.	NULL
L.	NULL
&	NULL
Baeuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

10	NULL
,	NULL
3805-3817	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Miner	NULL
,	NULL
Z.	NULL
,	NULL
Kerppola	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
Lambert	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
Verdine	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Curran	NULL
,	NULL
T.	NULL
&	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
365	NULL
,	NULL
352-355	NULL
.	NULL

Ghosh	NULL
,	NULL
P.	NULL
,	NULL
Tan	NULL
,	NULL
T.	NULL
H.	NULL
,	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
Sica	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Young	NULL
,	NULL
H.	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
,	NULL
1696-1700	NULL
.	NULL

Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
Science	NULL
248	NULL
,	NULL
1349-1356	NULL
.	NULL

Kang	NULL
,	NULL
S.-M.	NULL
,	NULL
Beverly	NULL
,	NULL
B.	NULL
,	NULL
Tran	NULL
,	NULL
A.-C.	NULL
,	NULL
Brorson	NULL
,	NULL
K.	NULL
,	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
&	NULL
Lenardo	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Science	NULL
257	NULL
,	NULL
1134-1138	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Valge-Archer	NULL
,	NULL
V.	NULL
E.	NULL
&	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
356	NULL
,	NULL
801-804	NULL
.	NULL

Berg	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
Pullen	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Fazekas	NULL
,	NULL
de	NULL
St.	NULL
Groth	NULL
,	NULL
B.	NULL
,	NULL
Mathis	NULL
,	NULL
D.	NULL
,	NULL
Benoist	NULL
,	NULL
C.	NULL
&	NULL
Davis	NULL
,	NULL
M.	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
58	NULL
,	NULL
1035-1046	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Luo	NULL
,	NULL
C.	NULL
,	NULL
Kerppola	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
Badalian	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Ho	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Burgeon	NULL
,	NULL
E.	NULL
,	NULL
Lane	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
Lambert	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
Curran	NULL
,	NULL
T.	NULL
,	NULL
Verdine	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Hogan	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1993	NULL
)	NULL
Science	NULL
262	NULL
,	NULL
750-754	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
Schreiber	NULL
,	NULL
E.	NULL
,	NULL
Matthias	NULL
,	NULL
P.	NULL
,	NULL
Muller	NULL
,	NULL
M.	NULL
M.	NULL
&	NULL
Schaffner	NULL
,	NULL
W.	NULL
(	NULL
1989	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17	NULL
,	NULL
6419	NULL
.	NULL

Choi	NULL
,	NULL
M.	NULL
S.	NULL
K.	NULL
,	NULL
Brines	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
Holman	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

&	NULL
Klaus	NULL
,	NULL
G.	NULL
G.	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Immunity	NULL
1	NULL
,	NULL
179-187	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
Miner	NULL
,	NULL
Z	NULL
.	NULL

&	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

151	NULL
,	NULL
837-848	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
Valge-Archer	NULL
,	NULL
V.	NULL
E.	NULL
&	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

148	NULL
,	NULL
1240-1250	NULL
.	NULL

Lederer	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Liou	NULL
,	NULL
J.S	NULL
.	NULL

,	NULL
Todd	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
Glimcher	NULL
,	NULL
L.	NULL
H.	NULL
&	NULL
Lichtman	NULL
,	NULL
A.	NULL
H.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

152	NULL
,	NULL
77-86	NULL
.	NULL

Granelli-Piperno	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Nolan	NULL
,	NULL
P.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

147	NULL
,	NULL
2734-2739	NULL
.	NULL

Go	NULL
,	NULL
C.	NULL
&	NULL
Miller	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175	NULL
,	NULL
1327-1336	NULL
.	NULL

DeGrazia	NULL
,	NULL
U.	NULL
,	NULL
Felli	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Vacca	NULL
,	NULL
A.	NULL
,	NULL
Farina	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
Maroder	NULL
,	NULL
M.	NULL
,	NULL
Cappabianca	NULL
,	NULL
L.	NULL
,	NULL
Meco	NULL
,	NULL
D.	NULL
,	NULL
Farina	NULL
,	NULL
M.	NULL
,	NULL
Screpanti	NULL
,	NULL
I.	NULL
,	NULL
Frati	NULL
,	NULL
L.	NULL
&	NULL
Gulino	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180	NULL
,	NULL
1485-1497	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
&	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1072	NULL
,	NULL
129-157	NULL
.	NULL

Ochi	NULL
,	NULL
Y.	NULL
,	NULL
Koizumi	NULL
,	NULL
T.	NULL
,	NULL
Kobayashi	NULL
,	NULL
S.	NULL
,	NULL
Phuchareon	NULL
,	NULL
J.	NULL
,	NULL
Hatano	NULL
,	NULL
M.	NULL
,	NULL
Takada	NULL
,	NULL
M.	NULL
,	NULL
Tomita	NULL
,	NULL
Y	NULL
.	NULL

&	NULL
Tokuhisa	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

153	NULL
,	NULL
3485-3490	NULL
.	NULL

Shimizu	NULL
,	NULL
H.	NULL
,	NULL
Mitomo	NULL
,	NULL
K.	NULL
,	NULL
Watanabe	NULL
,	NULL
T.	NULL
,	NULL
Okamoto	NULL
,	NULL
S.	NULL
&	NULL
Yamamoto	NULL
,	NULL
K.	NULL
(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10	NULL
,	NULL
561-568	NULL
.	NULL

Goldfeld	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
Strominger	NULL
,	NULL
J.	NULL
L.	NULL
&	NULL
Doyle	NULL
,	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

174	NULL
,	NULL
73-81	NULL
.	NULL

Rincon	NULL
,	NULL
M.	NULL
&	NULL
Flavell	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

13	NULL
,	NULL
4370-4381	NULL
.	NULL

Boise	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
Petryniak	NULL
,	NULL
B.	NULL
,	NULL
Mao	NULL
,	NULL
X.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Wang	NULL
,	NULL
C.	NULL
Y.	NULL
,	NULL
Lindsten	NULL
,	NULL
T.	NULL
,	NULL
Bravo	NULL
,	NULL
R.	NULL
,	NULL
Kovary	NULL
,	NULL
K.	NULL
,	NULL
Leiden	NULL
,	NULL
J.	NULL
M.	NULL
&	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
,	NULL
1911-1919	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Science	NULL
242	NULL
,	NULL
540-546	NULL
.	NULL

Ziegler-Heitbrock	NULL
,	NULL
H.	NULL
W.	NULL
,	NULL
Wedel	NULL
,	NULL
A.	NULL
,	NULL
Schraut	NULL
,	NULL
W.	NULL
,	NULL
Strobel	NULL
,	NULL
M.	NULL
,	NULL
Wendelgass	NULL
,	NULL
P.	NULL
,	NULL
Sternsdorf	NULL
,	NULL
T.	NULL
,	NULL
Bauerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Haas	NULL
,	NULL
J.	NULL
G.	NULL
&	NULL
Riecthmuller	NULL
,	NULL
G.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
17001-17004	NULL
.	NULL

